如何让桃子快速变大_国产精品视频网站大全套_国产成人综合亚洲欧美在线n互動交流_網友分享国产日韩欧美高清心得_免费毛片视频重口_午夜少妇嗷嗷嗷叫视频播放_和校花同居的日子2_亚洲字幕无码木天堂字幕无码_91人成免费观看_久久久精品免费观看

In-depth cooperation for win-win progress

On June 28, 2021, Kexing Biopharmaceutical Co., Ltd. and Taizhou Mabtech Pharmaceutical Co., Ltd. (hereinafter referred to as Taizhou Mabtech) signed the CMAB008 International Exclusive Commercial License Agreement. The signing of the agreement was immediately followed by the two sides’ close coordination in the registration of infliximab in 32 countries for overseas commercial cooperation, making significant progress. Both sides are now ready for in-depth cooperation after several rounds of communication and negotiation.

Kexing Biopharm granted the exclusive promotion right of infliximab (Reminton?)
On March 31, 2022, Kexing Biopharmaceutical Co., Ltd. (hereinafter referred to as "the Company" or "Kexing Biopharm") announced that the Exclusive Promotion Service Agreement for Infliximab (Reminton?) in Chinese Mainland was signed with Taizhou Mabtech, granting Kexing Biopharm the exclusive promotion right of infliximab (Reminton?) in Chinese mainland.

There is a large, long-term unmet need for infliximab as it currently targets more than 10 million people in China, a number that continues to grow. In view of this and with the exclusive promotion right of the drug in the Chinese mainland, we will be able to enrich our product lines and expand the scope of cooperation in the field of autoimmunity. This development is expected to enhance our influence, competitiveness and future business performance.